Seaport’s US$225m raise could fuel depression treatment breakthrough – Health Tech World
Seaport Therapeutics, the biopharma developing new neuropsychiatric medicines, has closed a US$225m series B funding round. The financing brings the total capital raised by Seaport to US$325m since its launch in April. The programmes in Seaport’s pipeline use its “Glyph” platform, designed to help advance clinically active drugs that were previously hindered by their potential […]